<DOC>
	<DOCNO>NCT00761592</DOCNO>
	<brief_summary>This pilot study estimate treatment effect two different type botulinum toxin type A treatment Blepharospasm . Blepharospasm characterise excessive contraction muscle around eye lead repetitive blinking sustained closure eyelid .</brief_summary>
	<brief_title>Comparison Two Botulinum Type A Products Treatment Blepharospasm</brief_title>
	<detailed_description />
	<mesh_term>Blepharospasm</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Diagnosed benign essential blepharospasm Received ≥20U/eye BOTOX® least one visit prior study entry require , investigator opinion , dose study injection visit . Combined Jankovic Rating Score &gt; 2 Female subject pregnant , breastfeeding , childbirth potential practice birth control . Profound atrophy muscle target area ( ) injection . Myasthenia Gravis , LambertEaton Syndrome , Amyotrophic Lateral Sclerosis disease might interfere neuromuscular function . Known significantly impaired renal and/or hepatic function</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>